Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Natural Killer/T-cell Lymphoma × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 44 Melanoma 19 Squamous Cell Carcinoma of Head and Neck 15 Neoplasms 15 Neoplasm Metastasis 15 Skin Neoplasms 11 Lung Neoplasms 10 Recurrence 8 Head and Neck Neoplasms 8 Carcinoma, Squamous Cell 8 Carcinoma, Renal Cell 8 Colorectal Neoplasms 7 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 6 Breast Neoplasms 6 Adenocarcinoma 6 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 5 Carcinoma, Merkel Cell 5 Carcinoma, Basal Cell 5 Carcinoma 5 Pancreatic Neoplasms 4 Multiple Myeloma 4 Glioblastoma 4 Colonic Neoplasms 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Mycosis Fungoides 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3

Interventions

isatuximab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04763616 2021-09-24

ICING

Samsung Medical Center

Phase 2 Recruiting

Natural Killer/T-cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡